Selank is a synthetic heptapeptide built from the immune-active fragment of tuftsin, and the published record groups its studied effects into a few clusters: anxiety, cognition, mood, immune function, and neurotransmitter regulation. The honest bottom line up front is that evidence strength varies sharply by effect. The anxiolytic (anti-anxiety) action carries the most human support, while most other claims rest on rodent or mechanistic data, and Selank is registered as a medicine in Russia but is not approved by the FDA or EMA.
Selank is a synthetic tuftsin-derived heptapeptide studied for anxiolytic, nootropic, mood, neurochemical, and immunomodulatory effects, with anxiety the best-supported in humans and most other effects resting on preclinical rodent or mechanistic data.
The anxiolytic effect is the single best-studied property of Selank and the one with the most direct human data behind it. In small controlled Russian studies of patients with generalized anxiety disorder, intranasal Selank produced anxiety reductions reported as broadly comparable to the benzodiazepine medazepam, but without the sedation, muscle relaxation, memory impairment, or physical dependence that limit that drug class. The evidence remains small-sample and single-country, so the signal is the most credible of Selank's claims while still falling short of large multicenter randomized trials.
| Property | Selank (intranasal) | Benzodiazepines |
|---|---|---|
| Anxiety reduction | Comparable to medazepam in small GAD trials | Established, first-line |
| Sedation / muscle relaxation | Not reported | Common |
| Physical dependence / withdrawal | Not reported | Well-documented |
| Mechanism | Indirect GABA modulation, no benzodiazepine-site binding | Direct GABA-A benzodiazepine-site binding |
In small controlled Russian trials of generalized anxiety disorder, intranasal Selank produced anxiety reductions reported as comparable to the benzodiazepine medazepam without the sedation, muscle relaxation, or physical dependence typical of that class.
Selank is frequently labeled a nootropic, but that reputation rests on a much thinner evidence base than its anxiolytic record. Most cognitive findings come from rodent studies, where the peptide improved learning and memory retention mainly under stress or induced impairment rather than at healthy baseline. Human evidence for genuine cognitive enhancement is limited and hard to separate from the mental clarity that simply follows reduced anxiety.
Selank's nootropic reputation rests largely on rodent studies showing memory improvement under stress or impairment, and the claim that it sharpens cognition in healthy people is an extrapolation from animal and mechanistic data rather than a conclusion from human trials.
Selank's behavioral effects trace to a coordinated action across several neurotransmitter systems rather than a single receptor target. The clearest thread is GABAergic modulation that reduces anxiety without the direct GABA-A benzodiazepine-site binding responsible for sedation, alongside reported shifts in serotonin turnover in mood- and anxiety-related regions. Much of this map is built from animal brain-tissue measurements and inferred pathways rather than direct human neurochemical readouts.
Selank is reported to reduce anxiety by modulating GABAergic tone without binding the GABA-A benzodiazepine site, alongside serotonergic and enkephalin-linked effects, though most of this map derives from animal brain-tissue studies rather than direct human measurements.
The BDNF findings are a specific, mechanism-level piece of the Selank research and read most accurately as preclinical evidence rather than a demonstrated human benefit. Gene-expression studies in rodents report that Selank alters BDNF and related plasticity genes in the hippocampus, the region tied to learning, memory, and stress adaptation. Because BDNF supports neuronal survival and synaptic strengthening, this supplies a plausible biological bridge to Selank's claimed behavioral effects, but the changes have not been reproduced as measured BDNF shifts in humans.
Rodent gene-expression studies report that Selank raises BDNF and plasticity-associated gene expression in the hippocampus, a mechanistic rationale for its central-nervous-system effects that has not been confirmed as measured BDNF change in humans.
For a neutral, primary-source reading, Selank's human evidence base is small, geographically concentrated, and methodologically limited. The clinical work is a modest number of mostly Russian trials in generalized anxiety and related neurotic and asthenic conditions, generally small in sample size, rarely the large multicenter double-blind randomized designs that anchor Western drug approvals, and largely published in Russian with limited independent replication. The animal and mechanistic literature is considerably larger, which creates a characteristic imbalance: the strength of evidence is effect-specific, not uniform.
| Claimed effect | Strength of human evidence |
|---|---|
| Anxiolytic | Strongest; small Russian GAD trials, promising but not definitive |
| Cognitive / nootropic | Weak; largely preclinical and extrapolated |
| Antidepressant / mood | Weak; overlaps anxiety relief, no dedicated trials |
| Immune / antiviral | Weakest; in-vitro and animal data, no clinical indication |
Selank is registered as a medicine in Russia but is not approved by the FDA or EMA, and its human evidence is effect-specific rather than uniform, with only the anxiolytic effect resting on direct clinical trials and most other claims resting on preclinical data.
Selank's immune effects are not an add-on curiosity; they follow directly from its lineage. The peptide is a synthetic analog built on the tuftsin fragment (the Thr-Lys-Pro-Arg sequence), and tuftsin is a naturally occurring immunostimulating peptide, so an immunomodulatory profile is expected from the structure itself. Reported effects include shifts in cytokine and interleukin activity, though the evidence is dominated by in-vitro, animal, and blood-sample studies rather than clinical trials of a therapeutic immune benefit.
Selank is a synthetic analog of the tuftsin fragment Thr-Lys-Pro-Arg and has been reported to shift cytokine and interleukin activity, an immunomodulatory profile grounded in its structure but demonstrated mainly in in-vitro and animal studies rather than clinical trials.
One of the more mechanistically distinctive aspects of Selank is how it engages the endogenous opioid system indirectly rather than through direct receptor stimulation. Research indicates that it inhibits the enzymes that break down enkephalins, the body's own opioid-like peptides, raising their concentration and extending their half-life in blood and tissue. Because it amplifies endogenous activity rather than flooding receptors, the research literature does not report the euphoria, tolerance, or physical dependence characteristic of opioid drugs.
Selank inhibits enkephalin-degrading enzymes, raising endogenous enkephalin levels and extending their half-life rather than binding opioid receptors directly, which is why the preclinical literature reports none of the euphoria, tolerance, or dependence seen with opioid drugs.
Educational use only. This article describes what the published scientific and clinical literature reports about Selank. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
